MARKETSPERPSLIVESOCIAL
RESEARCH
โ€”Cashโ€”Portfolio
TrendingElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentionsFinanceTech & Science
Kalshi
๐•โ—Žโ™ช๐ŸŽฎ๐Ÿ‘ฝin

PRODUCT

  • Perpetual Futures
  • Markets
  • Incentive program
  • Institutions
  • API & developers

COMPANY

  • About
  • Kalshi Research
  • Blog
  • Careers
  • Policy Center
  • Brand Kit

HELP

  • Help Center
  • FAQ
  • Fee schedule
  • Trading hours
  • Regulatory

ยฉ 2026 Kalshi Inc. ยท All rights reserved

PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals

Trading involves risk and may not be appropriate for everyone. Members can lose the full cost of entering any transaction, including fees. Consider carefully whether trading is suitable for you in light of your financial resources and experience. All trading decisions are your own responsibility and made at your own risk; information is provided for convenience on an "as is" basis. Past performance does not guarantee future results. This site is an unaffiliated frontend demo built for educational purposes and is not the real Kalshi exchange โ€” no markets, funds, or orders are real.

BrowseLiveSearchSocial
All markets
IPOsKPIsM&ACEOsIndicesProduct launches
BiotechCompute
Foreign ExchangeInterest RatesMatch Ups
All marketsCompaniesIndustriesMarkets

Biotech

BIOTECH

FDA decision: Iberdomide by BMS/Celgene (in 2026)

Dec 31 @ 11:59PM

a full approval or an accelerated approval
1.19x84%
$4.5k vol1 market
BIOTECH

FDA decision: Ivonescimab by Summit Therapeutics (in 2026)

Dec 31 @ 11:59PM

a full approval or an accelerated approval
1.45x69%
$2.7k vol1 market
BIOTECH

FDA decision: Brepocitinib by Priovant Therapeutics (in 2026)

Dec 31 @ 11:59PM

a full approval or an accelerated approval
1.19x84%
$1.7k vol1 market
BIOTECH

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

Dec 31 @ 11:59PM

a full approval or an accelerated approval
1.30x77%
$1.2k vol1 market
BIOTECH

FDA decision: Rusfertide by Protagonist Therapeutics (in 2026)

Dec 31 @ 11:59PM

a full approval or an accelerated approval
1.19x84%
$1.3k vol1 market
BIOTECH

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)

Dec 31 @ 11:59PM

a full approval or an accelerated approval
1.25x80%
$687 vol1 market
BIOTECH

FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (in 2026)

Dec 31 @ 11:59PM

a full approval or an accelerated approval
1.09x92%
$605 vol1 market
BIOTECH

FDA decision: BBP-418 by Ml Bio Solutions Inc. (in 2026)

Dec 31 @ 11:59PM

a full approval or an accelerated approval
16.67x6%
$39 vol1 market
BIOTECH

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)

Dec 31 @ 11:59PM

a full approval or an accelerated approval
1.35x74%
$346 vol1 market
BIOTECH

FDA decision: Venglustat by Sanofi (in 2026)

Dec 31 @ 11:59PM

a full approval or an accelerated approval
1.20x83%
$370 vol1 market
BIOTECH

FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

Dec 31 @ 11:59PM

a full approval or an accelerated approval
1.47x68%
$237 vol1 market
BIOTECH

FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)

Dec 31 @ 11:59PM

a full approval or an accelerated approval
1.33x75%
$177 vol1 market